Coulter Partners Top hires for VC & PE portfolio companies Q1-2024
Search Highlights
Recent top global hires for Venture Capital and Private Equity portfolio companies, covering a broad range of disciplines and sectors across Life Sciences, Health and Tech.
This quarter’s successful placements include:
Function |
Focus area |
Location |
CEO |
Therapeutic devices |
Austria |
Chief Business Officer |
Precision biologics |
US |
Chief Financial Officer |
Remote monitoring |
France |
Chief Strategy Officer |
Medical devices |
Israel |
Chief Medical Officer |
Radiopharmaceuticals |
US |
Chief of Staff |
Vaccines |
Denmark |
VP Global Program Leader, Respiratory |
Multi-modality biotech |
UK |
VP Technology & Product Development |
DNA technology |
UK |
Controller |
Contract manufacturing |
US |
Senior Director Pharmaceutical Development |
Drug delivery |
Ireland |
Director Market Access & Pricing Global |
Ophthalmology |
Italy |
Investment Manager Digital Health |
Life sciences investor |
Netherlands |
General Manager Infectious Diseases |
Biocluster |
France |
Board Director |
Personalized digital health |
Switzerland |
Board Director |
Electronic medical instrumentation |
US |
Board Director |
Immunotherapies |
Sweden |
Newly opened projects include:
Function |
Focus area |
Location |
CEO |
Medical devices |
Belgium |
CEO |
Precision medicines |
US |
Chief Commercial Officer |
Contract research organization (CRO) |
UK |
Chief Development Officer |
Protein degradation |
DACH |
Chief Scientific Officer |
Small molecules |
Spain |
Chief Financial Officer |
Gene therapy |
US |
Chief Operating Officer |
Incubator/ tech transfer |
UK |
Head of Strategy & Commercial Excellence |
Drug delivery systems |
Germany |
SVP, Head of Business Development |
Drug discovery services |
Germany |
VP of Science |
Precision nutrition |
UK |
VP, Head of Translational Development |
Gene editing |
Spain |
VP Research & Preclinical |
Synthetic biology |
UK |
VP Business Development |
tRNA technologies |
US |
Life Sciences Partner |
Life sciences investor |
Italy |
Board Director |
T-cell therapies |
US/ Europe |